Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKO 004

Drug Profile

AKO 004

Alternative Names: AKO-004

Latest Information Update: 08 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akome Biotech
  • Developer Akome Biotech; Complutense University Madrid
  • Class Antiparkinsonians; Dimethylamines; Drug withdrawal therapies; Indoles; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules; Tryptamines; Vascular disorder therapies
  • Mechanism of Action Apoptosis stimulants; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 04 Mar 2022 Akome Biotech and Universidad Complutense de Madrid agree to co-develop psychedelic compounds for the treatment of Alzheimer's disease, Parkinson's disease, major depressive disorder and ischaemic stroke
  • 04 Mar 2022 Preclinical trials in Parkinson's disease in Spain, Canada
  • 26 Jul 2021 Akome Biotech files for patent protection with the USPTO for AKO 004 in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top